Aktie SPARK THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Spark Therapeutics, Inc.

Aktien

US84652J1034

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB
One of Nature’s journals publishes article about CombiGene’s epilepsy project
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies Updates Cash Runway Guidance
Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders
Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders
Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
Watch CEO Jan Nilsson’s presentation at Aktiedagen Göteborg
CombiGene presents at Aktiedagen Göteborg on Monday 16 May
BioStock: CombiGene strives for a broader pipeline
Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022
CombiGene launches new website
Year-end report January-December 2021 CombiGene AB (Publ)
BioStock: CombiGene's CEO gives business development update
CombiGene’s and Neurochase’s preclinical study provides valuable information for the upcoming long-term studies in toxicology and biodistribution
GMP production of CG01 made available for preclinical studies planned to enable First in Human study
Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel's University City Campus
BioStock: CombiGene's CEO about the path to the first clinical trial
CombiGene and Spark Therapeutics plan to expand the clinical development program to include the U.S. as well as Europe
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe
University of Pennsylvania : Novel gene therapy for hemophilia A
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. Aktie
  4. Nachrichten Spark Therapeutics, Inc.
  5. Andere Sprachen